
Lenny Dang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3388489/publications.pdf

Version: 2024-02-01



LENNY DANC

#	Article	IF	CITATIONS
1	Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model. Blood Cells, Molecules, and Diseases, 2022, 95, 102660.	1.4	9
2	A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. Blood, 2022, 140, 2053-2062.	1.4	34
3	The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model. Journal of Clinical Investigation, 2021, 131, .	8.2	39
4	Vorasidenib (AC-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. ACS Medicinal Chemistry Letters, 2020, 11, 101-107.	2.8	99
5	Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. ACS Medicinal Chemistry Letters, 2018, 9, 300-305.	2.8	292
6	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations. Cancer Discovery, 2017, 7, 478-493.	9.4	350
7	AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency. Blood, 2017, 130, 1347-1356.	1.4	88